Cyclo Therapeutics Files 8-K: Acquisition, Delisting, Control Change
| Field | Detail |
|---|---|
| Company | Cyclo Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Mar 26, 2025 |
| Risk Level | high |
| Sentiment | mixed |
Sentiment: mixed
Topics: acquisition, delisting, change-of-control, corporate-events
Related Tickers: CTDH
TL;DR
Cyclo Therapeutics 8-K: Acquisition done, but facing delisting and control changes. Big shakeup incoming.
AI Summary
Cyclo Therapeutics, Inc. filed an 8-K on March 26, 2025, indicating several significant events. These include the completion of an acquisition or disposition of assets, a notice of delisting or failure to meet continued listing rules, material modifications to security holder rights, and changes in control of the registrant. The filing also covers departures of directors or officers, elections of directors, appointments of officers, and compensatory arrangements. Additionally, it includes Regulation FD disclosures and financial statements and exhibits.
Why It Matters
This 8-K filing signals major corporate events for Cyclo Therapeutics, including potential delisting and changes in control, which could significantly impact its stock and operations.
Risk Assessment
Risk Level: high — The filing indicates potential delisting and changes in control, which are significant risks for investors.
Key Players & Entities
- Cyclo Therapeutics, Inc. (company) — Registrant
- 0001437749-25-009255 (filing_id) — Accession Number
- 20250326 (date) — Filing Date
- 20250325 (date) — Period of Report
- CTD HOLDINGS INC (company) — Former Company Name
- CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT INC (company) — Former Company Name
FAQ
What specific assets were acquired or disposed of by Cyclo Therapeutics?
The filing does not specify the details of the acquisition or disposition of assets, only that it occurred.
What are the reasons for Cyclo Therapeutics' potential delisting or failure to meet listing rules?
The filing does not specify the exact reasons for the potential delisting or failure to meet listing rules.
What changes in control of Cyclo Therapeutics are indicated in the filing?
The filing indicates that changes in control of the registrant have occurred, but does not provide specific details.
Were there any departures of directors or officers, or appointments of new ones?
Yes, the filing indicates departures of directors or certain officers, election of directors, and appointment of certain officers.
What is the significance of the Regulation FD Disclosure mentioned in the filing?
The Regulation FD Disclosure item indicates that material non-public information may have been disclosed, requiring public dissemination.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 26, 2025 regarding Cyclo Therapeutics, Inc..